Literature DB >> 26004920

Lipoprotein apheresis.

Vijay G Bhoj1, Bruce S Sachais.   

Abstract

Lipoprotein apheresis is an extracorporeal therapy whereby apo B-containing lipoproteins (LDL, vLDL, and Lp(a)) are selectively removed from the plasma of a patient. It is a variation of plasma exchange, which non-selectively removes all plasma proteins. Lipoprotein apheresis is most commonly used to treat patients with familial hypercholesterolemia, but is also often used for other hyperlipidemic patients, including those with elevated Lp(a), to limit and/or reverse the atherosclerotic complications of high cholesterol. Herein, we provide an overview of lipoprotein apheresis including indications, techniques, efficacy, and adverse events, as well as guidelines and other considerations important for selection of patients for this therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26004920     DOI: 10.1007/s11883-015-0516-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  43 in total

1.  Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group.

Authors:  B R Gordon; S F Kelsey; D W Bilheimer; D C Brown; P C Dau; A M Gotto; D R Illingworth; P H Jones; S F Leitman; J S Prihoda
Journal:  Am J Cardiol       Date:  1992-10-15       Impact factor: 2.778

Review 2.  Lipidfiltration--safe and effective methodology to perform lipid-apheresis.

Authors:  Reinhard Klingel; Patrick Mausfeld; Cordula Fassbender; Britta Goehlen
Journal:  Transfus Apher Sci       Date:  2004-06       Impact factor: 1.764

3.  Effect of low-density lipoprotein cholesterol apheresis on blood viscosity.

Authors:  Patrick M Moriarty; Cheryl A Gibson; Kenneth R Kensey; William Hogenauer
Journal:  Am J Cardiol       Date:  2004-04-15       Impact factor: 2.778

4.  LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia.

Authors:  C Rovers; M G Netea; N de Bont; P N Demacker; C Jacobs; B J Kullberg; J W Van der Meer; A F Stalenhoef
Journal:  Atherosclerosis       Date:  1998-11       Impact factor: 5.162

5.  A new approach to the management of familial hypercholesterolaemia: Removal of plasma-cholesterol based on the principle of affinity chromatography.

Authors:  P J Lupien; S Moorjani; J Awad
Journal:  Lancet       Date:  1976-06-12       Impact factor: 79.321

6.  Long-term effects of LDL apheresis in patients with severe hypercholesterolemia.

Authors:  Bruce S Sachais; Julie Katz; Joyce Ross; Daniel J Rader
Journal:  J Clin Apher       Date:  2005-12       Impact factor: 2.821

7.  Low-density lipoprotein apheresis therapy during pregnancy.

Authors:  L Cashin-Hemphill; M Noone; J F Abbott; C A Waksmonski; R S Lees
Journal:  Am J Cardiol       Date:  2000-11-15       Impact factor: 2.778

8.  Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems.

Authors:  W Knisel; A Di Nicuolo; M Pfohl; H Müller; T Risler; M Eggstein; E Seifried
Journal:  J Intern Med       Date:  1993-11       Impact factor: 8.989

9.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

Authors:  H Mabuchi; J Koizumi; M Shimizu; K Kajinami; S Miyamoto; K Ueda; T Takegoshi
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

10.  Plasma exchange in the management of homozygous familial hypercholesterolaemia.

Authors:  G R Thompson; R Lowenthal; N B Myant
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

View more
  1 in total

Review 1.  Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.

Authors:  Bhavin B Adhyaru; Terry A Jacobson
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.